Showing results (11-20 of 660) with videos related to
Sort By:
Pageof 66
Recent Patents on Anti-Cancer Drug Discovery|January 20, 2009
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicineMadeleine Hewish, Ian Chau, David CunninghamExpert Opinion on Pharmacotherapy|October 25, 2007
Capecitabine in advanced gastric cancerAlicia Okines, Ian Chau, David CunninghamSurgical Oncology Clinics of North America|November 22, 2011
Preoperative and postoperative chemotherapy for gastric cancerVikram K Jain, David Cunningham, Ian ChauPancreas|March 7, 2013
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancerRichard A Hubner, Fiona Worsnop, David Cunningham, et al.European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncologySarah Barton, Clare Peckitt, Francesco Sclafani, et al.Frontiers in Oncology|August 6, 2019
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination StrategiesOliver Butters, Kate Young, David Cunningham, et al.Seminars in Radiation Oncology|June 8, 2011
Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm?Eliza A Hawkes, David Cunningham, Diana Tait, et al.Future Oncology (London, England)|March 12, 2015
Pancreatic neuroendocrine tumors: a reviewKate Young, Ridhima Iyer, Daniel Morganstein, et al.Clinical Colorectal Cancer|December 17, 2013
A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancersFrancesco Sclafani, Elizabeth Smyth, David Cunningham, et al.Diseases of the Colon and Rectum|May 1, 2009
Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resectionThomas Yau, David Watkins, David Cunningham, et al.Pageof 66